Frederick Rau, MD
Obstetrics & Gynecology · Hartford, CTNPI 1194828137
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,838 of the $89,372 with a category attached, or 82.6%. AbbVie accounts for 94.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $62,068 and has fallen 99.4% since, to $355 in 2025. Among obstetrics & gynecology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $480.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$85K
- Covidien LP$1K
- Medtronic$1K
- Applied Medical Resources Corporation$759
- Pfizer$226
- Sumitomo Pharma America, Inc.$175
- plus $878 from 16 others
Across 45 payments — averaging $1281.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$37K
- Covidien LP$21K
What the payments were for
- Consulting fees$1,0001%
- Speaking & faculty fees$73,83883%
- Travel & lodging$10,74912%
- Food & beverage$3,7784%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 98 | $84,580 |
| Covidien LP | 11 | $1,500 |
| Medtronic | 13 | $1,255 |
| Applied Medical Resources Corporation | 3 | $759 |
| Pfizer | 13 | $226 |
| Sumitomo Pharma America, Inc. | 8 | $175 |
| Bayer | 6 | $119 |
| Minerva Surgical, Inc | 4 | $110 |
| Hologic Sales And Service, LLC | 2 | $108 |
| Mayne Pharma Commercial LLC | 5 | $101 |
| Avion Pharmaceuticals | 8 | $99 |
| Organon | 1 | $73 |
| Myovant Sciences Inc. | 3 | $58 |
| Exeltis, USA Inc. | 2 | $44 |
| Exact Sciences | 2 | $37 |
| Astellas Pharma US Inc | 1 | $27 |
| Convatec Inc. | 1 | $23 |
| Millicent US Inc | 1 | $22 |
| Sage Therapeutics, LLC | 1 | $17 |
| Coopersurgical, Inc. | 1 | $15 |
| Channel Medsystems, Inc. | 1 | $14 |
| Evofem Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$72,717
- ORIAHNN$11,850
- GelPOINT V-Path$622
How this compares
$89,372 in reported general payments places this provider in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EstringEstradiol | 35 | $18,867 |
| Estradiol | 100 | $8,785 |
| YuvafemEstradiol | 26 | $4,816 |
| Medroxyprogesterone Acetate | 21 | $924 |
| Junel FeNorethindrone-E.Estradiol-Iron | 17 | $383 |
| Metronidazole | 11 | $298 |
| ValacyclovirValacyclovir Hcl | 16 | $294 |
| Zolpidem Tartrate | 12 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEstring | $226 | $18,86735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.
Other obstetrics & gynecology in Hartford
- Alan FineHartford$30K
- Adam SteinbergHartford$23K
- Theodoros KapetanakisHartford$7K
- Michael BourqueHartford$4K
- Mary MinkinNew Haven$285K
- Alessandro SantinNew Haven$98K
- Peter AuerbachGroton$41K
- Shieva GhofranyStamford$33K
- Mark LeondiresNorwalk$31K
- Sean FlahertyHamden$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.